New hope for hard-to-treat leukemias? early trial combines four drugs
NCT ID NCT03595917
First seen Nov 04, 2025 · Last updated May 10, 2026 · Updated 27 times
Summary
This early-phase study tests a new drug (ABL001) combined with three other medicines (dasatinib, prednisone, and blinatumomab) for people with B-cell acute lymphoblastic leukemia or chronic myeloid leukemia that has a specific genetic marker (BCR-ABL positive). The main goal is to find the safest dose of ABL001 and see how well the combination works at putting the cancer into remission. About 40 to 65 adults will take part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Beth Israel Deaconess Medical Center
RECRUITINGBoston, Massachusetts, 02215, United States
Contact
-
Dana Farber Cancer Institute
RECRUITINGBoston, Massachusetts, 02115, United States
Contact
Contact
-
Roswell Park Comprehensive Cancer Center
RECRUITINGBuffalo, New York, 14203, United States
Contact Phone: •••-•••-••••
-
University of Chicago Comprehensive Cancer Center
RECRUITINGChicago, Illinois, 60637, United States
Contact Phone: •••-•••-••••
Conditions
Explore the condition pages connected to this study.